AzTrials
AzTrials

Acute Kidney InjuryPOAKIDSNCT07351149

Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery

An observational study of Acute Kidney Injury, run by Uppsala University at 16 sites in 10 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery. Urinary biomarkers are intended to be evaluated as predictors of PO-AKI in the same subjects. Read more about this study

Who is it for?
Ages 0 to 16 years
Conditions the study is for
Acute Kidney Injury
How many people
2,000 participants
Where
16 sitesin 10 countries
Study dates
1 Mar 2026to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Hospitalised paediatric patients undergoing major non-cardiac surgery in any of the specified investigator sites

Who may be able to join

  • Elective, urgent or emergency in-patient major non-cardiac surgical procedures performed under general anaesthesia with or without regional analgesia with a planned procedure duration of at least 60 minutes.
  • Paediatric patients (0-16 years old)

Who cannot join

  • Declined participation.
  • Ongoing renal replacement therapy
  • Acute Kidney Injury (according to KDIGO)
  • Known chronic kidney disease
  • Procedure involving surgery of the kidney
  • Procedures requiring clamping of blood flow to or from the kidney
Show all 9Show fewer
  • Body weight <2kg
  • Procedure involving contrast administration
  • Established rhabdomyolysis (CK-levels >1500 U/L)

Trial locations and contacts

16 sites in 10 countries. Contact the study team or a site near you to ask about taking part.

Robert Frithiof, Md, PhD contact

+46-72-2406252

robert.frithiof@uu.se

Arash Emami, MD contact

arash.emami@uu.se

16 sites in 10 countries

Sweden4 sites, 4 recruiting
  • Sahlgrenska University Hospital

    Gothenburg

    Elin Thorlacicus, MD, PhD, elin.thorlacius@vgregion.se

    Recruiting
  • Skåne University Hospital

    Lund

    Åsa Jungner, MD, PhD, asa.jungner@med.lu.se

    Not yet recruiting
  • Karolinska University Hospital

    Stockholm

    Andreas Andersson, andreas.andersson@regionstockholm.se

    Recruiting
  • Uppsala University Hospital

    Uppsala

    Robert Frithiof, MD, PhD, robert.frithiof@uu.se

    Arash Emami, MD, arash.emami@uu.se

    Recruiting

Other trials in Sweden

Switzerland3 sites, 3 recruiting
  • University Hospital Basel

    Basel

    Karin Becke-Jakob, MD, PhD, Karin.Becke-Jakob@ukbb.ch

    Not yet recruiting
  • University Hospital Bern

    Bern

    Alexander Fuchs, MD, PhD, alexander.fuchs@insel.ch

    Thomas Riva, MD, PhD, thomasriva@me.com

    Not yet recruiting
  • University Hospital Geneva

    Geneva

    Laszlo Vutskits, MD, PhD, laszlo.vutskits@hug.ch

    Not yet recruiting

Other trials in Switzerland

Australia2 sites, 2 recruiting
  • Perth Children's Hospital

    Perth, Western Australia, 6909

    Britta S von Ungern-Sternberg, MD, PhD, +61864564806, Britta.Regli-VonUngern@health.wa.gov.au

    Lliana B Slevin, BSc, Lliana.Slevin@thekids.org.au

    Not yet recruiting
  • The Kids Research Institute Australia

    Perth, Western Australia, 6909

    Britta S von Ungern-Sternberg, MD, PhD, +61864564806, Britta.Regli-VonUngern@health.wa.gov.au

    Lliana B Slevin, BSc, Lliana.Slevin@thekids.org.au

    Not yet recruiting

Other trials in Australia

Brazil1 site, 1 recruiting
  • Hospital das Clínicas HCFMUSP

    São Paulo

    Vinícius Quintao, MD, vinicius.quintao@hc.fm.usp.br

    Recruiting

Other trials in Brazil

Canada1 site, 1 recruiting
  • Montreal Children's Hospital

    Montreal, Quebec

    Gianluca Bertolizio, gianluca.bertolizio@mcgill.ca

    Not yet recruiting

Other trials in Canada

Croatia1 site, 1 recruiting
  • Children's Hospital Zagreb

    Zagreb

    Sandra Kralik, Sandra Kralik <sandra.kralik@gmail.com>

    Not yet recruiting

Other trials in Croatia

France1 site, 1 recruiting
  • Hospices Civils de Lyon

    Lyon

    Lionel Bouvet, MD, PhD, lionel.bouvet@chu-lyon.fr

    Not yet recruiting

Other trials in France

Italy1 site, 1 recruiting
  • IRCCS Istituto Giannina Gaslini

    Genova

    Edoardo del la Porta, MD, edoardolaporta@gaslini.org

    Nicola Disma, MD, PhD, nicoladisma@gaslini.org

    Recruiting

Other trials in Italy

Netherlands1 site, 1 recruiting
  • Radboud UMC

    Nijmegen

    Ignacio Malagon, JoseIgnacio.Malagon@radboudumc.nl

    Not yet recruiting

Other trials in Netherlands

Serbia1 site, 1 recruiting
  • University Hospital of Belgrade

    Belgrade

    Ivana Slevin, MD

    Recruiting

Other trials in Serbia

About this study

Official title: An International Multicentre Prospective Study of Postoperative Acute Kidney Injury in Hospitalized Paediatric Patients

This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery. Urinary biomarkers are intended to be evaluated as predictors of PO-AKI in the same subjects. The study employs modern standardized classifications for AKI to comprehensively address the issue of PO-AKI in children. Describing the incidence and identifying risk factors for PO-AKI will play a crucial role in developing preventive strategies aimed at reducing associated mortality and morbidity. Furthermore, investigating the relationship between urinary biomarkers of renal injury and PO-AKI will provide valuable insights into assessing postoperative renal function in paediatric patients, especially when repeated blood sampling is not feasible.

Read the detailed description

INTRODUCTION Acute Kidney Injury refers to a sudden impairment in renal function, reflected by increased plasma creatinine concentration and/or decreased urine output. Traditionally, only the most severe reduction in renal function with azotemia and anuria has been emphasised as significantly deleterious, but during the last decades evidence suggests that acute, relatively mild or moderate injury to the kidney portend serious clinical consequences. In critical illness, AKI is strongly associated with short-term mortality as well as chronic kidney disease, cardiovascular disease, and premature death, even when kidney function has recovered.

PO-AKI is characterized by a sudden and significant decline in renal function after surgery. In adults, it is established that PO-AKI is common, imposes a heavy burden of illness, is amenable to early detection and potential prevention and infers a high cost per person in management. There is also considerable variability in practice to prevent, diagnose, treat and achieve outcomes of AKI. Detailed knowledge of incidence rates, risk factors, and outcomes of PO-AKI have considerably enhanced our understanding of optimal treatment and prevention strategies.

Compared to the adult population, there remains a paucity of research data pertaining to PO-AKI for noncardiac surgery in children. However, there is a rational presumption that identifying, preventing, and treating a condition like PO-AKI, which carries enduring long-term consequences, would be particularly advantageous in paediatric patients. The known high burden of AKI in children who are critically ill or undergoing cardiac surgery underscore the importance of accurately and prospectively describing incidence and risk factors for paediatric PO-AKI.

Contemporary evidence advocates for the utilization of innovative urinary biomarkers in predicting and managing AKI. Nevertheless, additional studies are imperative to advance scientific and clinical comprehension regarding the optimal methods and timing for their application, not the least in the perioperative setting. The clinical promise of these biomarkers is particularly pronounced in paediatric populations due to the considerable impediment posed by the necessity for frequent blood sampling in diagnosing and staging PO-AKI within this group. Further investigation stands to enhance the understanding and implementation of these biomarkers, offering substantial potential benefits in the management of paediatric PO-AKI. However, data regarding PO-AKI in paediatric patients, especially those undergoing noncardiac surgery, are notably limited.

RESEARCH QUESTIONS

  1. What is the incidence of paediatric PO-AKI in hospitalized children after noncardiac surgery?
  2. Can urinary biomarkers, novel and established, accurately predict paediatric PO-AKI?
  3. What are the risk factors for AKI in children undergoing anaesthesia and surgery?

THE NEED FOR THE RESEARCH In adults, the impact of PO-AKI is extensively documented. Research indicates a notable disparity in the incidence of kidney failure among individuals who experience PO-AKI compared to those who do not. Specifically, at the one-year mark, the occurrence of kidney failure stands at 0.94% in individuals who have encountered PO-AKI, as opposed to a significantly lower rate of 0.05% in those without such a history. This trend persists over a decade, with kidney failure presenting in 0.4% of patients devoid of renal impairment post-surgery, whereas 2.3% of those affected by PO-AKI develop kidney failure within the same period. PO-AKI also further impair an already reduced renal function. While 7.3% of patients with Chronic Kidney Disease (CKD) progress to kidney failure over ten years, this figure elevates to 15.7% for individuals with CKD who have experienced PO-AKI. Even when kidney function fully recovers, individuals with a history of PO-AKI exhibit persistently inferior survival rates over a ten-year period. Additionally, patients who undergo PO-AKI face heightened risks of recurrent AKI episodes and future reliance on renal replacement therapy. Various postoperative complications, such as infections, prolonged mechanical ventilation, tracheostomy, and cardiovascular events, are more prevalent among patients who develop PO-AKI post-surgery compared to those who do not. Furthermore, PO-AKI incurs substantial hospitalization costs and increased utilization of resources. Thus, in adults PO-AKI pose a serious problem.

PAEDIATRIC POSTOPERATIVE ACUTE KIDNEY INJURY Millions of children undergo various surgical procedures globally each year, ranging from routine to complex surgeries. Limited research has focused on paediatric PO-AKI using contemporary criteria for renal dysfunction in noncardiac surgery. The majority of existing studies are retrospective, single-centre investigations reporting widely varied incidence of PO-AKI, ranging from 3.2% to 62.3%. Only one study is from Europe and two are prospective. Importantly, several studies focus solely on neonatal PO-AKI.

Large, well-performed studies in critically ill neonates and children demonstrate an incidence of AKI at rates of 29% and 27%, respectively. After paediatric cardiac surgery AKI is also common, although the prevalence is highly variable among different investigations. The estimated incidence is somewhere between 15%-60%, although a recent single-centre study using the KDIGO-criteria presented an incidence of 9.3%. AKI in neonates and children, regardless of triggering event, significantly correlates with in-hospital mortality and prolonged hospital stays. The long-term consequences of renal failure have been described as hypertension, proteinuria and chronic kidney disease, which is alarming since chronic renal pathology in youth is known to have extensive adverse effects.

URINARY BIOMARKERS OF RENAL DAMAGE Current diagnosis and staging of AKI rely on changes in plasma creatinine concentration or urine output. However, using plasma creatinine as a biomarker for renal dysfunction in the paediatric population presents several challenges. In early life, plasma creatinine levels primarily reflect maternal levels and are expected to decrease during the initial postnatal week. A failure of creatinine levels to decrease might signify impaired renal function, which may not be identified using the KDIGO definition. Additionally, plasma creatinine is a delayed marker of kidney function and may not accurately reflect minor renal impairment. Blood sampling, a requirement for diagnosis, poses practical and ethical challenges in children. These impediments collectively contribute to the problems in defining the incidence of PO-AKI and developing successful clinical trials and interventions for paediatric AKI.

Novel urinary biomarkers initially identified in high-risk populations show promise in early and precise diagnosis of paediatric AKI, potentially surpassing plasma creatinine analysis. However, there remains a lack of studies validating their use. A recent consensus statement recommends employing a combination of damage and functional biomarkers, along with clinical information, to identify high-risk patient groups, enhance AKI diagnosis, optimize care processes, and aid AKI management. Nevertheless, the same consensus statement also acknowledges that substantial knowledge gaps persist, necessitating further research. One significant obstacle in using urinary biomarkers for AKI is the release of endogenous substances during inflammation, clouding the interpretation of biomarker concentration increases in immune-stimulated patients. However, these challenges may be less significant in PO-AKI as children generally have fewer comorbidities and thus less acute/ chronic inflammation. Additionally, the timing of potential renal insults (anaesthesia and surgery) is known and can be accounted for. Different biomarkers reflecting increased urinary concentrations indicate damage at various nephron levels. Thus, if properly evaluated urinary biomarkers may prove to be an accurate and useful predictor of PO-AKI and also give mechanistic insight into the cause of the renal injury.

RISK FACTORS OF PAEDIATRIC POSTOPERATIVE ACUTE KIDNEY INJURY Several risk factors contribute to paediatric PO-AKI beyond the inflammatory response induced by surgery per se. Events in the perioperative setting, such as hypotension, hypoxia, infections, mechanical ventilation, fluid shifts, blood loss and exposure to nephrotoxic medications, are potential culprits. Renal hypoperfusion due to hypotension may occur due to various reasons, including hypovolemia due to blood loss or dehydration after fasting and inflammation-induced capillary leak. In adults it has been demonstrated that intraoperative hypotension is associated with AKI in noncardiac surgical populations. Longer hypotensive periods and lower blood pressure results in higher AKI probabilities. Infants with vasopressor treatment or high fluid infusion rates during abdominal surgery have higher risk of AKI compared with those without blood pressure support. Another potential risk factor is the choice of anaesthetic. It was demonstrated that volatile anaesthesia, compared with total intravenous propofol anaesthesia, is associated with reduced urine output and higher incidence of PO-AKI in adults. Finally, it was recently described that female sex confers protection against AKI. This has not previously been examined in a paediatric population or in the perioperative setting.

Keywords
Postoperative acute kidney injury, Pediatric kidney injury, Pediatric renal failure, Urinary biomarkers, Pediatric urinary biomarkers, Pediatric postoperative kidney injury, Pediatric anesthesia, Risk factors for pediatric acute kidney injury
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07351149
Study groupRoleWhat they receive
Children undergoing major non-cardiac surgery under general anaesthesiaEligible participants are children aged 0-16 years admitted for non-ambulatory, non-cardiac major surgery requiring general anaesthesia with an estimated duration of at least 60 minutes, including elective, urgent, and emergency procedures. Non-ambulatory surgery is defined as a planned overnight hospital admission following the procedure.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of postoperative AKI

    Incidence of postoperative AKI, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) creatinine criteria, based on changes in plasma/serum creatinine concentration from baseline within the postoperative period:

    • AKI Stage 1: Increase in plasma/serum creatinine ≥ 0.3 mg/dL (26.5 µmol/L) within 48 hours postoperatively OR 1.5-1.9 times baseline plasma/serum creatinine within 7 postoperative days.
    • AKI Stage 2: Increase in plasma/serum creatinine 2-2.9 times baseline p/s creatinine within 7 postoperative days.
    • AKI Stage 3: Increase in plasma/serum creatinine > 3 times baseline plasma/serum creatinine within 7 postoperative days OR increase in plasma/serum creatinine to 4.0mg/dL (353.6 µmol/L) OR Initiation of renal replacement therapy OR decrease in eGFR to < 35mL/min per 1.73 m2. All within 7 postoperative days.

    Baseline creatinine is defined as a plasma/serum creatinine value obtained within 24 hours prior of commencement of surgery.

    Measured: Within 7 postoperative days

Secondary outcomes (5)
  1. Agreement and association between changes in plasma/serum creatinine and urinary biomarkers of renal injury.

    Examples of urinary biomarkers: Neutrophil gelatinase-associated lipocalin (NGAL) Kidney injury molecule-1 (KIM-1) Tissue inhibitor of metalloproteinase 2 (TIMP-2) Insulin-like growth factor binding protein-7 (IGFBP-7) S100 calcium-binding protein A8 (S100A8) Osteoprotegerin (OPG) Galectin 3 Elastase Cystatin C Albumin/Creatinine-ratio

    Measured: Within 7 postoperative days

  2. Time from surgery to first AKI-qualifying creatinine

    Measured: Within 7 postoperative days

  3. Perioperative risk factors associated with postoperative AKI

    Measured: Within 7 postoperative days

  4. Diagnostic accuracy of plasma cystatin C for postoperative AKI and agreement with creatinine-based definitions.

    These analyses aim to evaluate how well urinary biomarkers discriminate AKI versus no AKI within the postoperative window. Biomarker distributions will be assessed and skewed biomarkers will be log-transformed as appropriate. Defined rules for values below/above assay limits (LLOQ/ULOQ) will be applied (e.g., imputation at LLOQ/2 for below LLOQ, or use of censored methods if needed) based on approach specified per assay. If urine dilution adjustment is used (e.g., indexing to urine creatinine), both raw and indexed values will be examined and available in main text or in supplement.

    The primary diagnostic measure will be the area under the receiver operating characteristic curve (AUROC) with 95% CI (e.g., DeLong method). ROC curves will be presented for each biomarker. If clinically meaningful cut-offs are available, sensitivity, specificity, positive/negative predictive values, and likelihood ratios will be reported with 95% CIs. If no established cut-offs exist, an "optimal" cut-of

    Measured: Within 7 postopertive days

  5. Associations between AKI and mortality, length of stay and renal replacement therapy

    Measured: Within 7 postoperative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2026
  2. Study start1 Mar 2026
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07351149
Sponsor's protocol ID
POAKIDS-2025-04168-02
Acronym
POAKIDS
Status last verified
Sep 2026
First submitted
9 Jan 2026
Last updated
29 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data underlying the results reported in publications from the POAKIDS study, including baseline characteristics, perioperative variables, outcome data, and biomarker measurements. All data will be fully anonymised at the individual level so that no participant can be identified.

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury, run by Uppsala University at 16 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Sweden, Switzerland, Australia, Brazil, Canada and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Robert Frithiof, Md, PhD (+46-72-2406252, robert.frithiof@uu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of postoperative AKI (time frame: Within 7 postoperative days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in